Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia

  • Vivian Leung ,

    Contributed equally to this work with: Vivian Leung, Frédérik Rousseau-Blass

    Roles Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing

    Affiliation Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, Québec, Canada

  • Frédérik Rousseau-Blass ,

    Contributed equally to this work with: Vivian Leung, Frédérik Rousseau-Blass

    Roles Data curation, Methodology, Writing – original draft, Writing – review & editing

    Affiliation Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, Québec, Canada

  • Guy Beauchamp,

    Roles Formal analysis, Methodology

    Affiliation Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, Québec, Canada

  • Daniel S. J. Pang

    Roles Conceptualization, Funding acquisition, Methodology, Supervision, Writing – original draft, Writing – review & editing

    Affiliation Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, Québec, Canada


Poor research reporting is a major contributing factor to low study reproducibility, financial and animal waste. The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines were developed to improve reporting quality and many journals support these guidelines. The influence of this support is unknown. We hypothesized that papers published in journals supporting the ARRIVE guidelines would show improved reporting compared with those in non-supporting journals. In a retrospective, observational cohort study, papers from 5 ARRIVE supporting (SUPP) and 2 non-supporting (nonSUPP) journals, published before (2009) and 5 years after (2015) the ARRIVE guidelines, were selected. Adherence to the ARRIVE checklist of 20 items was independently evaluated by two reviewers and items assessed as fully, partially or not reported. Mean percentages of items reported were compared between journal types and years with an unequal variance t-test. Individual items and sub-items were compared with a chi-square test. From an initial cohort of 956, 236 papers were included: 120 from 2009 (SUPP; n = 52, nonSUPP; n = 68), 116 from 2015 (SUPP; n = 61, nonSUPP; n = 55). The percentage of fully reported items was similar between journal types in 2009 (SUPP: 55.3 ± 11.5% [SD]; nonSUPP: 51.8 ± 9.0%; p = 0.07, 95% CI of mean difference -0.3–7.3%) and 2015 (SUPP: 60.5 ± 11.2%; nonSUPP; 60.2 ± 10.0%; p = 0.89, 95%CI -3.6–4.2%). The small increase in fully reported items between years was similar for both journal types (p = 0.09, 95% CI -0.5–4.3%). No paper fully reported 100% of items on the ARRIVE checklist and measures associated with bias were poorly reported. These results suggest that journal support for the ARRIVE guidelines has not resulted in a meaningful improvement in reporting quality, contributing to ongoing waste in animal research.


Accurate and complete reporting of animal experiments is central to supporting valid, reproducible research and to allow readers to critically evaluate published work. Poor or absent reporting is associated with deficiencies in experimental design that introduce bias and exaggerated effect sizes in to the literature [1, 2]. As a result, irreproducible animal research has significant ethical and financial costs [3]. The use of animals in poorly designed studies and in efforts to reproduce such studies represents a failure to uphold the 3Rs (refine, reduce, replace) of animal research [4]. Incomplete reporting of research contributes to a waste of funding, with a conservative estimate for preclinical research, of US$28 billion annually [3].

To address low standards of reporting, the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines for reporting were published in 2010 [5, 6]. The ARRIVE guidelines are summarized by a 20 item checklist that includes reporting of measures associated with bias (randomization, blinding, sample size calculation, data handling) [7, 8]. Over 1000 journals have responded to publication of the guidelines by linking to it on their websites and in their instructions to authors [9]. The effect of these endorsements is unknown. For the majority of existing health research guidelines, the impact of journal support for other reporting guidelines on guideline adherence in published papers is unclear [10]. The impact of the CONSORT guidelines for the reporting of randomised controlled trials have been evaluated more than other reporting guidelines, and current evidence suggests that though reporting of some items has improved, overall standards of reporting remain low [11].

To our knowledge, there have been no studies comparing reporting standards between journals classified as ARRIVE guideline supporters and non-supporters. Furthermore, no studies examining adherence to the ARRIVE guidelines have been conducted in the veterinary literature. We hypothesized that papers published in supporting journals would have greater adherence to the guidelines, and therefore higher reporting standards, than those published in non-supporting journals. Additionally, we hypothesized that papers published in supporting journals would show a greater improvement in reporting standards since the guidelines became available. To test these hypotheses the related subjects of anesthetic and analgesic efficacy and animal welfare were selected for study.


Journal and paper selection

Journals were categorized as ARRIVE supporters (SUPP) or non-supporters (nonSUPP) based on whether the ARRIVE guidelines were mentioned in their instructions to authors when beginning the study (November 2016). Editorial offices of SUPP journals confirmed by email that the ARRIVE guidelines were included in the instructions to authors before December 2014. Papers were selected from a selection of journals from these two categories (SUPP and nonSUPP) from two years: 2009 (pre-ARRIVE) and 2015 (post-ARRIVE). SUPP journals were: Journal of the American Association for Laboratory Animal Science, Comparative Medicine, Animal Welfare, Laboratory Animals and Alternatives to Animal Experimentation. NonSUPP journals were: Applied Animal Behaviour Science and Experimental Animals. Journals were selected based on an initial search for those publishing papers on the predetermined subjects of interest (welfare, analgesic and anesthetic efficacy). Additionally, none of the selected journals had previously been included in a study assessing adherence to the ARRIVE guidelines.

An initial screening of all papers was performed by a single author (VL) by manual search of tables of contents, using titles, abstracts and keywords to identify relevant papers. Papers were selected based on subject and study type. A second screening was performed by two authors (VL and FRB) during the full text evaluation of the selected papers. Anesthesia or analgesia papers described studies assessing the efficacy of anesthetics or analgesics as a primary objective. Animal welfare papers described studies where the objective was to improve the well-being of animals used in research. Only prospective in vivo studies were included. Case studies were excluded.


Evaluation of adherence to the ARRIVE guidelines was performed independently by two authors (VL and FRB). The ARRIVE checklist [6] of 20 items and 46 associated sub-items was operationalized and used as the basis for evaluation (Table 1). Descriptors were developed by consensus to promote consistency during evaluation (Table 1). Items without associated sub-items were categorized as either not reported, partially reported or fully reported. Items with sub-items were categorized as not reported if no sub-items were reported, partially reported if only some sub-items were reported and fully reported if all sub-items were reported. For example, for Item 6 (Study design, Table 1), the item would only be classified as fully reported if all sub-items (6a-d) were reported, otherwise it would be classified as partially (3 or fewer sub-items reported) or not reported (none of the 4 sub-items reported).

Table 1. The ARRIVE guidelines checklist: Operationalized items and sub-items to facilitate assessment of reporting [6].

A sub-item was added to the original ARRIVE checklist to clarify drug use (sub-item 7e, Table 1). Where items or sub-items were considered not applicable, no score was entered. For example, a paper on zebra fish would have the sub-items bedding materials, access to water and humidity classed as not applicable.

Item and sub-item scores were compared between authors and differences resolved by consensus (with DP).


Each paper was assessed against the 20 items of the ARRIVE guidelines, generating percentages of fully reported items. From this, mean percentages of items were calculated for each journal type during each publication year. Following Levene’s test revealing heterogeneity of variances, an unequal variance t-test was used to compare these mean percentages between journal types (SUPP 2009 vs nonSUPP 2009; SUPP 2015 vs nonSUPP 2015) and between years (SUPP 2009 vs. SUPP 2015; nonSUPP 2009 vs. nonSUPP 2015). Correction for multiple comparisons was not applied as comparisons between identical items were viewed as independent from other items. The overall quality of item reporting was classified as well (> 80%), average (50–80%) or poor (< 50%) [12]. For each journal type, the percentages of individual items and sub-items that were fully, partially or not reported were compared between years with a chi-square test. Additionally, to provide an overall impression of reporting standards in 2015 data from both journal types were pooled.


After initial screening, 271 papers were identified. Thirty-five papers were excluded following full text evaluation, leaving 236 papers included in the final analysis (SUPP 2009: n = 52; SUPP 2015: n = 61; nonSUPP 2009: n = 68; nonSUPP 2015: n = 55, Fig 1). One item and one sub item (generalizability/translation (item 19), number of independent replication (sub- item 10c)) were removed before analysis as they were only applicable in a small number of papers (4/236 and 10/236, respectively). Data are available from the Harvard dataverse [13].

Fig 1. Flow diagram of paper selection process.

Papers were selected from studies reporting research in anesthesia, analgesia and animal welfare from 5 veterinary journals.

The percentages of fully reported items between journal types were similar in 2009 (p = 0.07) and 2015 (p = 0.89; Table 2). The percentage of fully reported items increased significantly from 2009 to 2015 for both SUPP (p = 0.02) and nonSUPP (p = 0.0001; Table 2) journals. Although both journal types showed improvements from 2009 to 2015, neither improved significantly more than the other (absolute difference in change between nonSUPP–SUPP = 3.3%, p = 0.09 [95% CI -0.5–4.3%]).

Table 2. Overall reporting quality in journals supporting (SUPP) and not supporting (nonSUPP) the ARRIVE guidelines for 2009 and 2015.


Despite minimal improvements in overall reporting standards between 2009 and 2015, several individual items showed significant improvement in full reporting. For SUPP journals, these items were the abstract (from 69.2 to 91.8%, p = 0.003), housing and husbandry (from 3.9 to 21.3%, p = 0.01) and sample size (from 3.8 to 21.3%, p = 0.01; Table 3). For nonSUPP journals, the following items were increasingly fully reported from 2009 to 2015: ethical statement (from 36.8 to 81.8%, p < 0.0001); experimental animals (from 1.5 to 10.9%, p = 0.04) and interpretation/scientific implications (from 10.3 to 38.2%, p = 0.0004; Table 3).

Table 3. Papers fully reporting ARRIVE checklist items in supporting (SUPP) and non-supporting (nonSUPP) journals in 2009 and 2015.

In SUPP journals, sample size was reported at least partially by all papers in 2009 but was not reported in 9.8% of papers in 2015 (p = 0.03, S1 Table and Table 3). In both SUPP and nonSUPP journals, items that were frequently not reported in both 2009 and 2015 were baseline data, numbers analyzed and funding.

Pooling the percentage of fully reported items in 2015 from both journal types revealed that items with excellent (> 80%), average (50–80%) and poor (< 50%) reporting was distributed in to thirds (Fig 2). Title, abstract, background, objectives, ethical statement, experimental outcomes, and outcomes and estimation were well reported. In contrast, ethical statement, baseline data, numbers analyzed, adverse events and funding were poorly reported.

Fig 2. Bar graph of papers fully reporting individual items from the ARRIVE checklist.

Data from papers published in 2015 were pooled from ARRIVE supporting (SUPP, n = 61 papers) and non-supporting (nonSUPP, n = 55 papers) journals. Broken horizontal lines indicate reporting quality thresholds: excellent (> 80%), average (50–80%) and poor (< 50%) [12].


There were significant improvements in percentages of papers reporting a small number of sub-items between years for each journal type though overall levels of reporting remained low (S2 Table). Notably amongst these were sub-items associated with bias: blinding (sub-item 6c), sample size calculation (sub-item 10b), allocation method (sub-item 11a) and data handling (sub-item 15b) (Fig 3) Randomization (sub-item 6b) was alone in being reported more than 50% of the time (Fig 3).

Fig 3. Radar plot of ARRIVE checklist sub-items associated with bias reported in ARRIVE supporting (SUPP) and non-supporting (nonSUPP) journals in 2015.


Numerous studies across different research fields have shown that reporting quality has remained low since the publication of the ARRIVE guidelines [12, 1418]. This is in spite of large scale support for the guidelines by biomedical journals and increasing awareness of the financial and ethical cost of irreproducible research [3, 5, 7, 19]. The results of our study confirm that reporting quality remains low and that journal support for the ARRIVE guidelines has not resulted in meaningful improvements in reporting standards.

Adherence to reporting guidelines remains low despite journal support

Reporting standards in this sample of anesthesia, analgesia and animal welfare papers was low, with little indication that the ARRIVE guidelines have made an impact in improving reporting standards. These findings echo those of others [8, 15, 16]. The data presented here, published 5 years after introduction of the ARRIVE guidelines, reflect the low reporting rates identified by Kilkenny et al. (2009) [5] that served as the catalyst for creation of the guidelines. As in those findings, reporting of important indicators of study design quality (randomization, blinding, sample size calculation and data handling) remain low.

A recent study of the veterinary literature that focused on reporting of randomization in randomised controlled trials found a higher percentage pf papers (49%, n = 106) reporting the allocation method than reported here (13–20% for SUPP and nonSUPP, respectively) [20]. This difference is likely to have resulted from selecting papers self-describing as randomised clinical trials.

With the small observed increase in reported items in both SUPP and nonSUPP journals, an increased awareness of reporting standards, such as the ARRIVE guidelines, cannot be ruled out. However, these increases were limited, with no significant differences in fully reported items between journal types in 2015 and, perhaps most importantly, the reporting of key sub-items indicating bias (randomization; sub-items 6b and 11a, blinding; sub-item 6c, animals excluded; sub-item 15b and sample size calculation; sub-item 10b) remained low [7, 8]. Similar findings have been reported in surveys of experimental animal models, including acute lung injury, peri-odontology, autoimmunity and neoplasia [1418]. Sample size justification, in particular, is consistently poorly reported, with reporting percentages ranging from 0–7% [1418]. This is an alarming figure given the impact it has on interpretation of findings and animal use [21].

A common feature in this and other studies of ARRIVE guideline adherence has been a lack of enforcement of reporting standards. In contrast, when reporting is mandatory, important improvements have been achieved [22, 23]. Following a change in editorial policy in 2013, the Nature research journals now require that authors accompany accepted manuscripts with a completed checklist identifying inclusion of key items associated with quality of reporting and study design [24]. This checklist has numerous items in common with those of the ARRIVE guidelines. In reviewing approximately 440 papers in each of two groups (those published in the Nature publishing journals and those from other publishers, before and after checklist implementation), the positive effect of the checklist was evident in that reporting of bias criteria (randomization, blinding, sample size calculation and data handling) [7] improved significantly from 0 to 16.4% [23]. While this number remains low, the percentage of papers from other publishers reporting these items was < 1% over the same time period. In striking contrast with the findings presented here and elsewhere [1418], introduction of the checklist was associated with a mention of sample size calculation in 58% (90/154) of papers, increasing from < 2% (3/192).

Suggestions to improved guideline adherence

To date, a change in editorial policy accompanied by mandatory submission of a reporting checklist is the only method shown to have resulted in an increase in reporting quality [23]. This clearly indicates that enforcement is required to generate a change in behavior. As others have suggested, achieving change in a well-established process, such as peer-review, is difficult [25]. Furthermore, placing the responsibility of policing guideline adherence on reviewers is unrealistic, when they are volunteering their time, usually busy and may share the same view of an unenforced request to complete a checklist [7, 25].

Other, albeit untested, suggestions to improve reporting standards include: 1. using a template of the methods section to require completion of desired items [25], 2. standardizing reporting of common outcomes by learned societies and research communities [15, 2629] and 3. mandating adherence to reporting standards at the stage of applying for federal authority to conduct research (in countries where this applies), perhaps in the form of study registration [30]. These suggestions, along with the checklist used by the Nature research journals, represent a shift away from the current format of the ARRIVE guidelines towards a shorter checklist. Irrespective of scope and format, it is clear reporting standards will remain low without some form of enforced adherence [15, 25]. An important consequence of enforced compliance, which must be considered when selecting a method to improve reporting, is the associated cost (time and financial resources) to publishers and authors, and striking an acceptable balance between an ideal and that which is feasible, practical and achievable.


Our data may have been skewed by the small number of journals in the nonSUPP group and any policies of individual journals on how compliance with the ARRIVE reporting guidelines were assessed. The choice of journals was limited due to the large number that have registered support for the ARRIVE guidelines and our choice of subject matter. While this reflects the success of the ARRIVE guidelines in being widely adopted, our data highlight that the relationship between guideline support and adherence merits investigation [15, 31]. Despite the low number of journals included, the risk of systematic journal bias is likely to be low given similar standards of reporting have been documented across a wide range of biomedical journals [12, 1418].


Journal support for the ARRIVE guidelines has not resulted in improved reporting standards, with the lowest levels of reporting associated with factors reflecting potential study bias. To achieve meaningful improvements in reporting standards, as a means to improve study reproducibility and reduce financial and animal waste, enforcement of reporting is necessary.

Supporting information

S1 Table. Papers partially reporting ARRIVE checklist items in supporting (SUPP) and non-supporting (nonSUPP) journals in 2009 and 2015.

N = total number of papers where the item was applicable. n = total number of papers partially reporting the item. p values are for comparisons between years for each journal type.


S2 Table. Papers fully reporting ARRIVE checklist sub-items in supporting (SUPP) and non-supporting (nonSUPP) journals in 2009 and 2015.

N = total number of journal articles where the sub-item was applicable; n = total number of journal articles reporting the sub-item. p values are for comparisons between years for each journal type.



Dr Michael E Mullins (Washington University School of Medicine) for inspiring the title of this paper.


  1. 1. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39: 2824–2829. pmid:18635842
  2. 2. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S, Macleod MR. Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler. 2010;16: 1044–1055. pmid:20685763
  3. 3. Freedman LP, Cockburn IM, Simcoe TS. The Economics of Reproducibility in Preclinical Research. PLoS Biol. 2015;13: e1002165. pmid:26057340
  4. 4. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. 1992 Available from:
  5. 5. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One. 2009;4: e7824. pmid:19956596
  6. 6. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8: e1000412. pmid:20613859
  7. 7. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490: 187–191. pmid:23060188
  8. 8. Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, et al. Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol. 2015;13: e1002273. pmid:26460723
  9. 9. Anon. ARRIVE: Animal Research Reporting In Vivo Experiments. National Centre for the Replacement, Refinement & Reduction of Animals in Research. Available from:
  10. 10. Stevens A, Shamseer L, Weinstein E, Yazdi F, Turner L, Thielman J, et al. Relation of completeness of reporting of health research to journals’ endorsement of reporting guidelines: systematic review. BMJ. 2014;348: g3804. pmid:24965222
  11. 11. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev. 2012;11: MR000030.
  12. 12. Delgado-Ruiz RA, Calvo-Guirado JL, Romanos GE. Critical size defects for bone regeneration experiments in rabbit calvariae: systematic review and quality evaluation using ARRIVE guidelines. Clin Oral Implants Res. 2015;26: 915–930. pmid:24766503
  13. 13. Leung V, Rousseau-Blass F, Pang DSJ. “ARRIVE guidelines study”. 2017 Database: Harvard dataverse [Internet]. Available from: Pang, Daniel, 2017, “ARRIVE guidelines study”,, Harvard Dataverse, V1
  14. 14. Avey MT, Moher D, Sullivan KJ, Fergusson D, Griffin G, Grimshaw JM, et al. The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research. PLoS One. 2016;11: e0166733. pmid:27855228
  15. 15. Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS Biol. 2014;12: e1001756. pmid:24409096
  16. 16. Liu Y, Zhao X, Mai Y, Li X, Wang J, Chen L, et al. Adherence to ARRIVE Guidelines in Chinese Journal Reports on Neoplasms in Animals. PLoS One. 2016;11: e0154657. pmid:27182788
  17. 17. Schwarz F, Iglhaut G, Becker J. Quality assessment of reporting of animal studies on pathogenesis and treatment of peri-implant mucositis and peri-implantitis. A systematic review using the ARRIVE guidelines. J Clin Periodontol. 2012;39 Suppl 12: 63–72.
  18. 18. Ting KH, Hill CL, Whittle SL. Quality of reporting of interventional animal studies in rheumatology: a systematic review using the ARRIVE guidelines. Int J Rheum Dis. 2015;18: 488–494. pmid:26082348
  19. 19. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2: e124. pmid:16060722
  20. 20. Di Girolamo N, Giuffrida MA, Winter AL, Meursinge Reynders R. In veterinary trials reporting and communication regarding randomisation procedures is suboptimal. Vet Rec. 2017;181: 195. pmid:28487452
  21. 21. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14: 365–376. pmid:23571845
  22. 22. Han S, Olonisakin TF, Pribis JP, Zupetic J, Yoon JH, Holleran KM, et al. A checklist is associated with increased quality of reporting preclinical biomedical research: A systematic review. PLoS One. 2017;12: e0183591. pmid:28902887
  23. 23. Macleod MR, group TNPQIPC. Findings of a retrospective, controlled cohort study of the impact of a change in Nature journals’ editorial policy for life sciences research on the completeness of reporting study design and execution. bioRxiv. 2017187245.
  24. 24. Anon. Reducing our irreproducibility. Nature. 2013;496: 398.
  25. 25. McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol. 2015;172: 3189–3193. pmid:25964986
  26. 26. Baker D, Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;242: 78–83. pmid:22119102
  27. 27. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40: 2244–2250. pmid:19246690
  28. 28. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11: 38–45. pmid:20184514
  29. 29. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, et al. Accelerating drug discovery for Alzheimer’s disease: best practices for preclinical animal studies. Alzheimers Res Ther. 2011;3: 28. pmid:21943025
  30. 30. Vogt L, Reichlin TS, Nathues C, Würbel H. Authorization of Animal Experiments Is Based on Confidence Rather than Evidence of Scientific Rigor. PLoS Biol. 2016;14: e2000598. pmid:27911892
  31. 31. Cressey D. Surge in support of animal-research guidelines. Nature 2016